Elanco Animal Health Inc
NYSE:ELAN
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
11.78
18.45
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Elanco Animal Health Inc
Elanco Animal Health Inc
Research & Development
Elanco Animal Health Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Elanco Animal Health Inc
NYSE:ELAN
|
Research & Development
-$342m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Research & Development
-$16.4B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-7%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Research & Development
-$9.5B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-10%
|
|
|
Pfizer Inc
NYSE:PFE
|
Research & Development
-$10.5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-4%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Research & Development
-$16B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-9%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Research & Development
-$10.5B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-8%
|
|
Elanco Animal Health Inc
Glance View
Elanco Animal Health Inc. has emerged as a leading player in the global animal health industry, driven by a commitment to improving the health and productivity of livestock and pets alike. With a history that dates back to the late 1950s, Elanco operates under the guiding principle that healthy animals lead to healthy societies, making their mission not just a business goal but a moral imperative. The company's expansive portfolio includes vaccines, parasiticides, antibiotics, and nutritional products, which cater to a diverse range of species including cattle, pigs, and companion animals. By leveraging cutting-edge research and development, Elanco continually innovates to address emerging challenges in animal health, such as antibiotic resistance and the demand for sustainable farming practices, thereby aligning itself with broader societal health agendas. For investors, Elanco presents a compelling opportunity anchored in robust financial performance and a resilient business model. The company's strategic acquisitions have bolstered its market presence, particularly following the acquisition of Bayer’s Animal Health business, which significantly expanded its product offerings and revenue base. Additionally, Elanco has demonstrated strong growth potential, driven by increasing global demand for protein and the human-animal bond that fuels spending on pet care. With a seasoned management team and a focus on sustainability and innovation, Elanco is well-positioned to capitalize on market trends while delivering value to shareholders. As the world navigates the complexities of food security and animal welfare, Elanco stands out as both a growth story and a responsible investment in the future of health.
See Also
What is Elanco Animal Health Inc's Research & Development?
Research & Development
-342m
USD
Based on the financial report for Sep 30, 2024, Elanco Animal Health Inc's Research & Development amounts to -342m USD.
What is Elanco Animal Health Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-5%
Over the last year, the Research & Development growth was -4%. The average annual Research & Development growth rates for Elanco Animal Health Inc have been 4% over the past three years , -5% over the past five years .
You don't have any saved screeners yet
